INDEGENE’S SaaS PLATFORM For Life Sciences Adds Syneos Health As Strategic Collaborator and Minority Investor

9 Jan 2021
INDEGENE’S SaaS PLATFORM For Life Sciences Adds Syneos Health As Strategic Collaborator and Minority Investor

Princeton/Bangalore, January 9, 2020 – Indegene, a leading Healthcare Tech firm focused on the global life sciences industry, announced Syneos Health (NASDAQ: SYNH) as a strategic collaborator and minority investor in Indegene Omnipresence Inc., a wholly-owned subsidiary of Indegene. Syneos Health is the only fully integrated biopharmaceutical solutions organization, and provides end-to-end drug development and commercialization solutions to biopharmaceutical customers in more than 110 countries.

Omnipresence is a next-generation unified customer experience platform for healthcare and life sciences organizations with CRM, omnichannel engagement, advanced analytics, and AI capabilities in a single unified platform. The Omnipresence platform, built as a strategic alliance with Microsoft since 2017, brings together Microsoft Azure analytics as well as Microsoft AI together with Microsoft Dynamics 365 and Power Platform for business applications, and Microsoft Office 365 and Teams for productivity and collaboration. Combined with Indegene’s deep industry expertise, analytics, and omnichannel engagement IP, Omnipresence enables life sciences organizations to elevate and transform the experiences they can deliver to healthcare professionals, patients, and business stakeholders.

“We are excited to welcome Syneos Health as an investor for Indegene’s Omnipresence subsidiary. This investment will further accelerate the roadmap and deployments of our Customer Experience Management (CXM) platform for life sciences and healthcare clients. Indegene Omnipresence truly applies the power of modern omnichannel technology and advanced capabilities such as machine learning to achieve best-in-class customer-centric experiences,” said Manish Gupta, co-founder and CEO of Indegene.

Dr. Rajesh Nair, co-founder and President, Indegene added, “Both Indegene and Syneos Health are experienced in life sciences clinical development, commercialization, and global enterprise scale engagements. With this investment, Indegene Omnipresence will significantly strengthen its position as thenext-generation Customer Experience Management platform through expanded global resources and expertise, providing a much-needed option to meet the dramatically changing needs of the industry.”

Sanjay Virmani, EVP with Indegene and lead of the Omnipresence initiative, will continue as the CEO of Indegene Omnipresence Inc.

Alistair Macdonald, CEO, Syneos Health commented, “We’re excited to partner with Omnipresence the innovative platform, underpinned by Microsoft technologies, to address customer demand to drive high-value commercial relationships in an increasingly competitive marketplace. Syneos Health’s Dynamic Assembly network is an open ecosystem of the most agile data and technology collaborators, such as Omnipresence, to strategically address our biopharmaceutical customers’ challenges.”

“Omnipresence is a good example of an industry-specific, multi-cloud solution built with Microsoft’s enterprise technologies working together in uniquely disruptive ways. We are excited to see Indegene add Syneos Health as another strategic collaborator in our joint mission to bring new value to life sciences and healthcare organizations,” said James Phillips, Corporate Vice President, Business Applications Group, Microsoft.

About Indegene

Indegene enables global healthcare organizations address complex challenges and drive better health and business outcomes by seamlessly integrating analytics, technology, operations, and medical expertise. Indegene is at the forefront of driving innovation by combining medical expertise with contemporary digital and artificial intelligence technologies; resulting in IP, patents, and transformational solutions for the life sciences industry.

About Syneos Health

Syneos Health is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Created through the merger of two industry-leading companies – INC Research and inVentiv Health – we bring together approximately 24,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies, and apply advanced business practices to expedite our customers’ delivery of important therapies to patients.

For further information, please contact:

For business queries, please contact:

Indegene, 150 College Rd W, Suite 104, Princeton, NJ 08540 W

For more details, please refer to: